On February 22, Fosun Pharma announced that its holding subsidiary Fosun Hongchuang received approval from the State Drug Administration for the approval of the ORIN1001 tablet developed by it for clinical trials in the treatment of idiopathic pulmonary fibrosis
Fosun Hongchuang intends to conduct Phase I clinical trials of the new drug in China (excluding Hong Kong, Macau and Taiwan, the same below) when conditions are met
ORIN1001 tablet is a first-in-class small molecule drug with a new enzyme-type target, a new mechanism of action and a new chemical structure type independently developed by the group (ie the company and its holding subsidiaries/units, the same below).
for the treatment of advanced solid tumors and idiopathic pulmonary fibrosis
As of the date of this announcement, the new drug is in Phase I clinical trials in the United States for the treatment of advanced solid tumors and idiopathic pulmonary fibrosis, respectively, for relapsed, refractory, and metastatic breast cancer (including triple-negative breast cancer) ) has been certified by the US FDA Fast Track Development Program (i.
Fast Track Review); the new drug is in Phase I clinical trials in China for the treatment of advanced solid tumors
As of the date of this announcement, no drug with the same target as this new drug has been launched globally
As of January 2022, the Group has invested approximately RMB 185 million (unaudited) in the current research and development of this new drug